| Literature DB >> 21940414 |
Alvin L Smith1, Marisa St Claire2, Srikanth Yellayi2, Laura Bollinger2, Peter B Jahrling2,1, Jason Paragas2, Joseph E Blaney1, Reed F Johnson1.
Abstract
The public health threat of orthopoxviruses from bioterrorist attacks has prompted researchers to develop suitable animal models for increasing our understanding of viral pathogenesis and evaluation of medical countermeasures (MCMs) in compliance with the FDA Animal Efficacy Rule. We present an accessible intrabronchial cowpox virus (CPXV) model that can be evaluated under biosafety level-2 laboratory conditions. In this dose-ranging study, utilizing cynomolgus macaques, signs of typical orthopoxvirus disease were observed with the lymphoid organs, liver, skin (generally mild) and respiratory tract as target tissues. Clinical and histopathological evaluation suggests that intrabronchial CPXV recapitulated many of the features of monkeypox and variola virus, the causative agent of smallpox, infections in cynomolgus macaque models. These similarities suggest that CPXV infection in non-human primates should be pursued further as an alternative model of smallpox. Further development of the CPXV primate model, unimpeded by select agent and biocontainment restrictions, should facilitate the development of MCMs for smallpox.Entities:
Mesh:
Year: 2011 PMID: 21940414 PMCID: PMC3352329 DOI: 10.1099/vir.0.036905-0
Source DB: PubMed Journal: J Gen Virol ISSN: 0022-1317 Impact factor: 3.891